Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REPAIR GETUG P16: stereotactic ablative reirradiation potentiated by metformin for relapse in previously irradiated prostate bed
2022-502642-27-00Phase 2Authorised
- Sponsor
- Institut Cancérologique de l'Ouest
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of metformin in prostate cancer (PCa), sponsored by Institut Cancérologique de l'Ouest. Planned start Apr 2024; status: authorised.
02
Drugs
metformin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2022-502642-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502642-27-00.